8-K: Boston Scientific Announces CFO Transition: Dan Brennan to Retire, Jon Monson Appointed as Successor

Boston Scientific reveals that CFO Dan Brennan will retire and Jon Monson will take over the role, effective June 30, 2025.

Summary

• Boston Scientific Corporation announced the retirement of Executive Vice President and Chief Financial Officer, Dan Brennan, effective June 29, 2025.
• Brennan will remain with the company as a senior advisor until October 3, 2025, receiving his current base salary of $880,000 prorated through his retirement date.
• Jonathan Monson, currently Senior Vice President, Investor Relations, will succeed Brennan as Executive Vice President and Chief Financial Officer, effective June 30, 2025.
• Monson's new role includes responsibilities for global controllership, global internal audit, corporate finance, treasury, corporate tax, investor relations, and corporate business development.
• Monson's compensation will include an annual base salary of $700,000 and eligibility for an 80% target incentive under the 2025 Annual Bonus Plan.
• He will also be eligible to defer up to 75% of his annual bonus under the Deferred Bonus Plan.
• Monson will receive a promotional equity award with a grant date fair value of $1,750,000, vesting 25% per year starting on the first anniversary of the grant date.
• He will also participate in the Executive Retirement Plan, potentially receiving a lump sum payment of up to 36 months of salary upon retirement.
• Monson is also eligible for payments and benefits under the company's Change in Control Agreement.

Sentiment

Score: 8

Explanation: The announcement is positive, highlighting a planned and orderly executive transition with positive comments from the CEO. The appointment of an experienced internal candidate is generally viewed favorably.

Positives

• A smooth transition is expected as Brennan and Monson will work closely together.
• Monson's extensive experience within Boston Scientific, including roles as Global Controller and Chief Accounting Officer, positions him well for the CFO role.
• Monson's compensation package includes a significant equity award, aligning his interests with shareholders.
• Brennan's continued service as a senior advisor ensures the company retains his expertise during the transition period.

Risks

• The transition of key leadership roles always carries inherent risks, although the overlap period should mitigate this.
• Unforeseen challenges may arise during the integration of Monson into his new responsibilities.

Future Outlook

The company anticipates a smooth transition with Brennan and Monson working together. Boston Scientific expects Monson to drive capability and talent development across the company's global Finance organization.

Management Comments

• 'I thank Dan for his incredible leadership and tremendous contributions to Boston Scientific,' said Mike Mahoney, chairman and chief executive officer.
• 'Dan is an exceptional leader, financial steward and teammate.'
• 'Jon is a proven leader who is known for his strategic mindset, diligent and thoughtful leadership and focus on high performance and continuous innovation,' said Mahoney.

Industry Context

Executive transitions are common in the medical device industry, and Boston Scientific's announcement reflects a planned succession. The appointment of an internal candidate like Monson suggests a focus on maintaining continuity and leveraging existing expertise.

Comparison to Industry Standards

• Executive compensation packages in the medical device industry typically include a mix of base salary, bonus, equity awards, and benefits.
• Monson's compensation appears competitive with industry standards for CFOs at similarly sized companies.
• Equity awards are a common tool to align executive incentives with shareholder value.
• Succession planning is a critical aspect of corporate governance, and Boston Scientific's announcement demonstrates a proactive approach.

Management Changes

Stakeholder Impact

• Shareholders: The orderly transition should reassure investors and maintain confidence in the company's financial leadership.
• Employees: The internal promotion may boost morale and demonstrate opportunities for career advancement within the company.
• Customers: No direct impact is expected.
• Suppliers: No direct impact is expected.
• Creditors: No direct impact is expected.

Next Steps

• Brennan and Monson will work together to ensure a smooth transition.
• The Company expects to enter into a Retirement Agreement with Mr. Brennan effective as of the Retirement Date.
• Monson's performance and base salary will be reviewed during the normal executive review process, expected to commence in the first quarter of 2026.
• A copy of the Change in Control Agreement will be distributed to Monson within his first thirty days in his new role.

Key Dates

Keywords

CFO, retirement, appointment, Jonathan Monson, Dan Brennan, Boston Scientific, executive, finance, investor relations